Zydus Group Latest Update, News And Press Releases - Zydus Life
WEBZydus Cadila’s Sitagliptin Base Tablets Receives Tentative Approval from FDA. Get all the latest Zydus Group information, News, Videos, Press Releases and updates here.
Zydus receives USFDA approval for ZITUVIO™ to treat adult …
WEBOct 20, 2023 · Zydus Lifesciences Limited announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for ZITUVIO™ (Sitagliptin) tablets, a diabetes drug. ZITUVIO™ is a...
Zydus announces exclusive licensing and supply agreement for …
WEB15 hours ago · AHMEDABAD, India, Sept. 13, 2024 /PRNewswire/ -- Zydus Lifesciences Ltd., a global innovation driven healthcare company announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Viwit Pharmaceuticals (Viwit), an innovation driven biopharmaceutical and healthcare company, for gadobutrol injection (generic version ...
Zydus Life shares gain on signing licensing & supply
WEB13 hours ago · Zydus Lifesciences share price gained in the opening trade on September 16 following the company's announcement of a licensing & supply agreement with US-based Viwit Pharmaceuticals. At 09:21am ...
Zydus receives USFDA approval for ZITUVIO™ to treat adult …
WEBOct 20, 2023 · Zydus Lifesciences Limited announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for ZITUVIO™ (Sitagliptin) tablets, a dipeptidyl peptidase-4 (DPP-4)...
Zydus aims to launch first new drug in US by early 2026
WEBFeb 27 (Reuters) - India's Zydus Lifesciences (ZYDU.NS) is aiming to launch its first new drug in the United States by early 2026, looking to tap into the multi-billion dollar market for treating...
Zydus Life arm signs exclusive US licensing and supply pact
WEB3 days ago · Shares of Zydus Lifesciences Ltd ended at ₹1,118.50, down by ₹1.65, or 0.15%, on the BSE. Zydus Lifesciences Ltd on Friday (September 13) said its wholly-owned subsidiary Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Viwit Pharmaceuticals for two gadolinium-based MRI contrast agents for the ...
Zydus appoints Mr. Punit Patel as President and CEO to lead its ...
WEBOct 16, 2023 · Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as 'Zydus') a discovery-driven, global lifesciences company announced the appointment of Mr. Punit...
WEBZydus Lifesciences Limited announced that the U.S. Food and Drug Administration approved its New Drug Application for ZITUVIOTM, a DPP-4 inhibitor for type 2 diabetes mellitus. Zydus did not mention semaglutide, a GLP-1 receptor agonist, in its press release or product information.
India's Zydus Lifesciences beats Q3 profit estimates; approves …
WEBFeb 9, 2024 · Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets.
Skip to content